South Korea’s Celltrion (Kosdaq: 068270) has announced the US launch of Steqeyma (ustekinumab-stba), a biosimilar to Stelara ...
Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...
Celltrion launches Steqeyma autoimmune treatment in U.S. market Celltrion unveils its competitive approach for Steqeyma in ...
STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as ...
Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...
South Korean biopharmaceutical company Celltrion announced Thursday that it has launched Steqeyma (ustekinumab), a biosimilar treatment for autoimmune diseases, in the US market. Steqeyma, a ...
Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It ...
Yonhap News Agency on MSN4d
Celltrion launches autoimmune disease treatment in U.S.Celltrion Inc., a major South Korean biopharmaceutical firm, said Thursday it has launched its biosimilar product for Stelara ...
JERSEY CITY, N.J., March 12, 2025 /PRNewswire/ -- Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following approval by the U ...
Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback